Kári Stefánsson, M.D., Dr. Med. has served as President, Chief Executive Officer and a Director since he co-founded deCODE in August 1996. Dr. Stefánsson was appointed to serve as the Chairman of Board of Directors in December 1999. From 1993 until April 1997, Dr. Stefánsson was a professor of Neurology, Neuropathology and Neuroscience at Harvard University. In addition, from 1993 through December 1996 he was Director of Neuropathology at Beth Israel Hospital in Boston, Massachusetts. From 1983 to 1993, he held faculty positions in Neurology, Neuropathology and Neurosciences at the University of Chicago. Dr. Stefánsson received his M.D. and Dr. Med. from the University of Iceland and is board-certified in neurology and neuropathology in the United States.

deCODE is a biopharmaceutical company applying its discoveries in human genetics to develop drugs and diagnostics for common diseases. The population approach and resources have enabled deCODE to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. The company takes advantage of 1,000 years of genealogical records kept by the Icelandic people, and of the willingness of Icelanders to make their DNA available to the company for study of genetic patterns in disease.


Poster [PDF]